FREE TRACKED SHIPPING ON ORDERS OVER $299 $125
Sale!

Tirzepatide – 10mg

Original price was: $64.99.Current price is: $55.24.

15% OFFOctober Research Event

In stock

SALE ENDS IN --D--H--M--S
SKU: TR-10MG Categories: ,
  • Research focus: Dual incretin-receptor signalling
  • Compound class: GIP and GLP-1 receptor agonist
  • Researchers are exploring: Appetite, blood-sugar and metabolic signalling
Fast Order ProcessingIn-stock orders prepared promptly
Tracking ProvidedEmailed when your order is on its way
Canadian SupportHelp when you need it

RESEARCH AT A GLANCE

A clearer view of the research landscape

01

Primary pathway

Dual incretin-receptor signalling

02

Researchers explore

glucose-responsive signalling, appetite regulation and metabolic pathways

03

Research coverage

Extensive clinical and translational research

Tirzepatide — 10mg

Product Overview

Tirzepatide is a synthetic peptide agonist with activity at both the GIP and GLP-1 receptors. It was engineered from a GIP-based sequence and includes structural modifications that support extended exposure.

Research Background

Laboratory studies indicate that tirzepatide does not engage its two receptors identically. Research has examined its relative receptor potency, cyclic-AMP signalling, beta-arrestin recruitment and receptor internalization, providing a useful model for biased and imbalanced dual-receptor agonism.

Current Areas of Investigation

Research applications include comparative receptor assays, pancreatic-cell signalling, metabolic-pathway models and studies comparing single- and multi-receptor incretin ligands.

In Plain Language

Researchers use tirzepatide to study how two nutrient-responsive hormone pathways work together in areas such as appetite cues, blood-sugar regulation and the biological response to food. GIP and GLP-1 receptors overlap in some functions but differ in receptor strength, signalling bias and tissue distribution.

In plain terms, the research asks how a combined signal may affect hunger, fullness, glucose-dependent insulin release and longer-term metabolic regulation. Studies have reported meaningful changes in glucose and body-weight measures, while mechanistic work continues to separate the contributions of GIP from GLP-1.

Product Specifications

  • Catalogue No.: TR
  • Vial Size: 10mg

Quality & Documentation

Lot-specific product documentation and Certificate of Analysis (COA) information may be available through AURAPEP where applicable.

Research Use Only

RESEARCH USE ONLY — NOT FOR HUMAN CONSUMPTION. Supplied strictly for laboratory, analytical and research purposes. Not intended for self-administration or to diagnose, treat, cure or prevent any disease.

AURAPEP RESEARCH LIBRARY

Related Research

Explore the scientific background, evidence and limitations associated with this research compound.

Compound & Pathway Profiles

Tirzepatide Research: Dual GIP/GLP-1 Receptor Signalling

How tirzepatide engages GIP and GLP-1 receptors, what clinical trials have reported, and why dual agonism must be evaluated as a complete molecule.

Established clinical evidence for authorized medicines · 9 minutes

Explore the complete Research Library

PRODUCT FAQ

Three common research questions

Explore concise, product-specific answers without leaving this page.

PRODUCT FAQ

Tirzepatide – 10mg

01

What is Tirzepatide and which pathway do researchers study?

Tirzepatide is studied in relation to dual incretin-receptor signalling. Researchers use it to investigate glucose-responsive signalling, appetite regulation and metabolic pathways.

02

What are researchers investigating?

The current research landscape includes Extensive clinical and translational research. Study designs may involve biochemical assays, cell systems, animal models or regulated human research depending on the compound, and results should be interpreted within the limits of each model.

03

How does it differ from related research compounds?

Tirzepatide engages both GIP and GLP-1 receptors. Semaglutide primarily focuses on GLP-1, while retatrutide adds glucagon-receptor activity to the GIP and GLP-1 pathways.

Research information is provided for scientific context. Product supplied for research use only.